21/07/2026 Nektar Therapeutics initiated the Phase 3 ZENITH AD Program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics initiated the Phase 3 ZENITH AD Program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis (Ref) Nektar Therapeutics announced the initiation of the two global registrational Phase 3, ZENITH AD-1 and ZENITH AD-2 trials evaluating rezpegaldesleukin (IL-2 receptor agonist) in patients who were ≥12 year

20/04/2026 Nektar Therapeutics announced results from Phase 2b study for rezpegaldesleukin in severe-to-very severe AA Biogen entered into agreement with TJ Biopharma for felzartamab in the Greater China Region Nektar Therapeutics announced results from Phase 2b study for rezpegaldesleukin in severe-to-very severe AA ( Ref ) Nektar Therapeutics announced topline results from its Phase 2b REZOLVE-AA/ NCT06340360 study, which evaluated rezpegaldesleukin (IL-2 pathway agonist) f

17/02/2026 Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD Nektar Therapeutics announced a research collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165 in multiple sclerosis Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD ( Ref ) Sanofi and Teva announced positive results from the Phase 2b RELIEVE UCCD LTE/NCT05668013 study of